China Biotech Oncology Out-Licensing (2020–2026): Deal Landscape, Asset Innovation, and Global Expansion Trends

Introduction

Between January 2020 and July 2026, China's biopharmaceutical sector underwent a structural transformation from a predominantly domestic-facing innovation ecosystem to a globally integrated source of oncology therapeutics. Out-licensing (对外授权)—whereby Chinese biotech companies grant overseas pharmaceutical or biotechnology partners rights to develop and commercialize China-originated cancer drug candidates outside Greater China—emerged as a defining strategic mechanism of this transformation. The aggregate value of out-licensing deals from greater China reached a record $137.7 billion in 2025 alone, representing a nearly tenfold increase from 2021 levels 23. Oncology consistently represented more than 70% of total transaction volume across this period 1. This narrative review synthesizes major oncology out-licensing transactions from 2020 to 2026, analyzes deal structures and asset characteristics, and evaluates implications for global oncology practice.

Deal Landscape: Volume, Value, and Inflection Points

The trajectory of China biotech out-licensing from 2020 onward reflects a clear and accelerating trend. Annual transaction volume rose from fewer than 10 deals per year before 2020 to 39 in 2020, 43 in 2021, 51 in 2022, and approximately 70 in 2023, with more than 15 of the 2023 transactions exceeding $1 billion in total potential value 1. Total aggregate deal value escalated sharply: $32.2 billion in 2022, $35.2 billion in 2023, $51.9 billion in 2024, and $137.7 billion in 2025 23; an alternative estimate using a narrower deal-scope methodology places the figure at $92.2 billion for the same period 25. The average total potential deal value rose nearly threefold, from approximately $546 million in 2022 to $1.5 billion in 2025, while average upfront fees (首付款) grew from roughly $25 million in 2021 to $77.7 million by early 2026 2325.

Three inflection points are discernible within this period. The first (2020–2022) was characterized by anti-PD-1 monoclonal antibody licensing, largely reflecting the maturity of Chinese companies in checkpoint inhibitor development. The second (2023–2024) was driven by an explosion of antibody-drug conjugate (ADC，抗体偶联药物) and bispecific antibody (双特异性抗体) partnerships, reflecting technical maturation in complex biologics engineering. The third, ongoing phase (2025–2026) is characterized by portfolio-level collaborations and co-development structures, including equity co-investment, which signal that multinational partners now view Chinese biotech discovery engines as strategically valuable platforms rather than merely sources of incremental individual assets 224.

Oncology Asset Characteristics: Modalities and Clinical Differentiation

Table 1. Representative China-Origin Oncology Out-Licensing Deals, 2020–2026

Biotheus was acquired by BioNTech in 2025 (an acquisition, not a licensing deal); included for completeness. Novartis terminated the tislelizumab agreement in 2023, returning rights to BeiGene, citing changes in the competitive PD-1 landscape. Total potential value was not realized. Note: "Up to" values for total potential deal value include milestones (里程碑付款) and royalties (销售提成/特许权使用费) contingent on clinical, regulatory, and commercial success. Total potential values should not be interpreted as guaranteed payments.

The dominant oncology modalities in this period were ADCs, bispecific antibodies, PD-1/PD-L1 checkpoint inhibitors, and emerging radiopharmaceuticals. ADCs function as precision "guided missiles," coupling a tumor-targeting antibody to a cytotoxic payload via a specialized chemical linker, enabling selective delivery of chemotherapy to cancer cells while reducing off-target toxicity. China has established itself as a global leader in ADC licensing, accounting for nearly 90% of all global ADC licensing activity during this period 25. Bispecific antibodies—engineered proteins that simultaneously engage two distinct molecular targets—represent a second dominant category. The PD-1/VEGF and PD-L1/VEGF bispecific designs (SSGJ-707, RC148, LM-299, BNT327) were particularly sought after, combining immune checkpoint inhibition with anti-angiogenesis to address the treatment plateau observed with single-mechanism immunotherapies 131416. Anti-PD-1 monoclonal antibodies, while representing the largest category by early deal count, became progressively commoditized; the 2023 termination of the BeiGene–Novartis tislelizumab deal exemplifies this dynamic, with Novartis citing substantial changes in the competitive PD-1 landscape 12. More than 50% of out-licensed pipelines at signing were in early development stages (preclinical through Phase I/II), indicating strong Western confidence in China's upstream innovation capabilities 1.

Deal Value and Commercial Structure

Deal economics reflect a tiered risk-sharing architecture. Upfront payments (首付款) ranged from $50 million (Novartis–Zonsen PepLib, radiopharmaceutical) to $1.25 billion (Pfizer–3SBio, Phase 3-ready bispecific antibody), with the majority of major oncology deals clustered between $170 million and $800 million upfront. Milestone payments (里程碑付款) typically constitute 60–80% of total potential deal value, structured across development, regulatory, and commercial thresholds 1. Royalties (销售提成/特许权使用费) on net sales outside Greater China are typically tiered (escalating with sales volume), with disclosed ranges suggesting 5% to double-digit percentages depending on asset stage, competitive dynamics, and target novelty.

Equity co-investment has become an increasingly prominent structural element. The Takeda–Innovent deal included a $100 million equity investment at a 20% premium to market price, signaling platform-level conviction 20. The Pfizer–Innovent portfolio collaboration structured four of twelve programs as co-development and co-commercialization arrangements with profit-sharing in the US and Europe, while Innovent retains Greater China rights—a model signaling genuine partnership rather than pure asset acquisition 924. The Bristol Myers Squibb–Hengrui collaboration ($15.2 billion total potential value) included both licensed programs and joint discovery activities, representing the most comprehensive strategic alliance to date 7.

Regional rights structures have evolved importantly. Whereas earlier deals (2020–2022) often involved near-complete global rights transfers, more recent transactions preserve meaningful Greater China commercialization rights for Chinese companies, reflecting both the strategic importance of the Chinese domestic market and the growing negotiating leverage of Chinese licensors 3.

Global Expansion Strategy and Medical Implications

For Chinese biotechs, out-licensing provides multiple strategic advantages: non-dilutive capital supporting clinical development without equity dilution; access to multinational partners' regulatory expertise with the FDA, EMA, and PMDA; established commercial infrastructure in major markets; and risk-sharing with well-capitalized partners 2. For Western pharmaceutical partners, these deals address urgent pipeline replenishment needs driven by approaching patent cliffs on blockbuster agents, leverage lower R&D costs in China, and secure access to differentiated modalities—particularly ADC payload engineering and bispecific antibody design—before competitors 223.

These transactions carry direct implications for medical professionals. The globalization of China-origin oncology trials—where Innovent leads Phase I execution before Pfizer assumes global development, for example—is likely to increase enrollment of Chinese patients in multinational oncology studies, potentially improving trial generalizability across diverse populations 24. Licensed assets targeting historically difficult-to-treat cancers (gastric, pancreatic, and Claudin-18.2-overexpressing tumors via IBI343; rare EGFR-mutant NSCLC via Sunvozertinib; BCMA-targeted multiple myeloma via the Janssen–Legend CAR-T model) may expand therapeutic options in areas of high unmet need 181920. The emerging strategy of combining PD-1/VEGF bispecific antibodies with ADCs—as planned by AbbVie combining RC148 with its investigational ADC telisotuzumab adizutecan—may reshape combination therapy paradigms in solid tumors 14.

Risks and Limitations

Several risk factors merit attention. Geopolitically, a bipartisan bill introduced in June 2026 aims to subject US–China biotech transactions to outbound investment screening, citing national security concerns, building on the BIOSECURE Act passed in the US annual defense spending bill 2126. Legislative uncertainty may slow deal closures or alter structural terms, though as of mid-2026, deal activity has remained robust 25. Clinically, deal terminations underscore that "total potential value" figures reflect aspirational rather than guaranteed payments; Novartis's termination of the tislelizumab agreement in 2023, citing shifts in the competitive landscape, serves as a critical precedent 12. Data quality and trial design scrutiny by the FDA and EMA remain ongoing considerations, as Western regulators assess clinical evidence generated in Chinese trials. Concerns about the inadvertent impact of restrictive policies on Chinese American scientists and cross-border scientific collaboration also warrant acknowledgment 27.

Conclusion

From 2020 to July 2026, China-originated oncology assets have transitioned from domestically focused, fast-follower development programs toward globally licensed, often first-in-class or best-in-class drug candidates sought by the world's largest pharmaceutical companies. The deal landscape has evolved from single-asset PD-1 antibody licensing toward complex portfolio collaborations spanning ADCs, bispecific antibodies, cell therapies, small molecules, and radiopharmaceuticals, with total potential values reaching $15.2 billion for individual partnerships. For oncologists, clinical researchers, and medical affairs teams, these transactions signal an expanding pipeline of novel oncology agents with potential implications for treatment paradigm evolution across solid and hematologic malignancies. Sustained monitoring of clinical trial outcomes, regulatory approvals, geopolitical policy developments, and real-world efficacy data will be essential to assess the full clinical and therapeutic impact of this unprecedented wave of China biotech global expansion 22325.